A cosmld containing eight exons of the gene coding for the microtubule-associated tau protein was subjected to the exon trapping assay. All the constitutive exons contained in the cosmld (4, 5, 7 and 9) were efficiently captured regardless of size. Of the four alternatively spliced exons, three (3,4A and 8) were not isolated by the assay, but the behavior of exon 6 depended on the Identity of its flanking exons.
INTRODUCTION
The human gene which codes for the neuron-specific microtubuleassociated protein tau contains at least sixteen exons, of which six are cassettes ( Figure 1A ). Exons 4A, 6 and 8 have recently been found in the human genome (1), but not yet in human cDNAs; in rodents the former two are found in tau mRNAs of the peripheral nervous system (2, 3) . Exons 2, 3 and 10 are adultspecific in the central nervous system (4 -8) . Furthermore, the expression patterns of exons 2 and 3 (3 is never found without 2) indicate that these two exons are not equivalent with regard to splicing.
In the present study, we have used a cosmid containing eight exons (3 to 9, Figure IB ) of the human tau gene as a model substrate for exon trapping (9) . All the constitutive exons were efficiently captured, but the behavior of the alternatively spliced ones varied. The results suggest that this assay system, although entirely reliable with constitutive exons, may both under-and overestimate the potential cDNA species arising from a gene.
MATERIALS AND METHODS
Cell culture COS stock cell cultures were maintained in Dulbecco's modified Eagle medium (GIBCO-BRL) supplemented with 10% fetal bovine serum (GIBCO-BRL, heat-inactivated at 56°C for 1 hour).
Plasmid construction
All human tau genomic fragments originated from cosmid x6, which contains a 35 kbp insert cloned into the BamHI site of pWE15 ( Figure IB; 1) . Restriction mapping and partial sequencing showed that the x6 insert includes tau exons 3 to 9 and the 3' end of exon 2, truncated at an internal Sau3AI site (the cosmid library was generated by partially digesting human genomic DNA with Sau3AI, pooling the larger fragments and inserting them into the BamHI site of pWE15; R. Tanzi, personal communication). The tau fragments were cloned into eukaryotic expression vectors pSPLl (9) and pSVIRB ( Figure 2A ). The latter is a derivative of pSVI2 (10) in which the BamHI site in the second exon and the EcoRI site in the second intron of the rat insulin gene are unique. Chimeric constructs which included exons 2 to 9 ( Figure 3A) were produced by standard cloning methodology (11) , using the unique BamHI and EcoRI restriction sites in pSPLl and pSVIRB introns, respectively, as convenient insertion points for the relevant tau genomic fragments.
Transfections and RNA preparation
Plasmid DNA was purified using Qiagen Tip-20's according to the manufacturer's protocol (Diagen Inc.) or by cesium chloride banding, according to Sambrook et al. (11) . Plasmids were introduced into COS cells by either the calcium phosphate (11; Promega) or the lipofectase (12; GIBCO-BRL) method. Cells were plated on 100 mm plates and fed two hours prior to transfection. Upon reaching -40% confluence, each plate was transfected with 10/tg of construct DNA. The medium was changed 16 hours after addition of the calcium phosphate/DNA precipitate, without glycerol shock. Total RNA was isolated 48 hours post-transfection by the RNAzol method (13) according to the manufacturer's instructions (Cinna/Bkrtecx Laboratories, Houston, TX).
Reverse transcription and polymerase chain reactions
For PCR analysis of RNA, 3/tg of total RNA from transiently transfected COS cells were reverse transcribed using either random hexamers or oligomer SA4 (Table I) , which is specific for pSPLl, and 200 units of reverse transcriptase (RNAase HS uperscript, GIBCO-BRL), in a total volume of 20/xl for either 30 min or 1 hour at 42°C. The reaction was then treated with RNAase H (GIBCO-BRL) for 10 min at 55°C. Part of this reaction mix (5/tl) was then diluted to a final volume of 50^1, the concentrations of the buffer and dNTPs were adjusted for PCR and the mixture was amplified (30 cycles of denaturation at 94°C for 1 min, annealing at 55 °C for 1 min, extension at 72°C for 2 min for pSVIRB constructs; 35 cycles of denaturation at 94°C for 45 sec, annealing at 58°C for 30 sec, extension at 72°C for 1 sec for pSPLl constructs). The primers used are listed in Table I and shown in Figure 2A . The pSPLl and pSVIRB DNAs were used as controls ( Figure 3B ). The reverse transcribed, PCR-amplified (RT-PCR) product of any construct which was larger in size from that of spliced pSPLl or pSVIRB was cloned and sequenced.
Cloning of RT-PCR products
The fragments generated by RT-PCR were cloned by two methods: 1) The PCR products from pSVIRB were denatured for 2 min at 90°C in 'forward heat' buffer (11), phosphorylated in the presence of kinase 'forward' buffer, lOOmM ATP and 10 units of T4 polynucleotide kinase (New England Biolabs), run on a low melt agarose gel, extracted from the agarose by treatment with /3-agarase (New England Biolabs) and blunt-end ligated into Smal-digested dephosphorylated pKS + -Bluescribe (Stratagene); 2) The RT-PCR products from pSPLl were subjected to another PCR amplification with nested primers (SD1 and SA1, Figure 2A ). These secondary PCR primers contained 4 repeats of the trimer CUA, U being deoxyuracil (14; Figure 2B ). This base is cleaved off by uracil DNA glycosylase, thus producing 3' overhangs that can anneal to vector pUC19 which has been engineered to contain complementary overhangs (14; GIBCO-BRL).
Sequencing
Plasmid DNA was prepared by either alkaline lysis (11) (19) . Alternatively, the PCR products were sequenced by the dsDNA cycle sequencing system (20; GIBCO-BRL). The sequences were resolved on a denaturing (8.3 M urea) 6% (w/v) polyacrylamide gel and analyzed using the University of Wisconsin software package (21) .
RESULTS
The constitutive tau exons are efficiently captured but three of the cassette tau exons are not amplified Human tau exons 3 to 9 were inserted into expression vectors and transiently transfected into COS cells. The sizes of the inserts, exons and flanking introns are shown in Figure 3A .
The RT-PCR results show that all the constitutive tau exons (4, 5, 7, 9) contained in the cosmid were present in the mRNA of the expression constructs ( Figure 3, constructs 2, 4, and 6 ). Furthermore, sequencing of the RT-PCR products shows that these exons were spliced correctly; no cryptic 5' or 3' splice sites were utilized.
The insert containing tau exons 8 and 9 was placed in vector pSPLl without checking for orientation. In this case, there were two PCR products ( Figure 3B ). The major one contained exon 9; sequencing of the minor one ( Figure 3B , band X) showed that it contained a 162 nucleotide insert from the nonsense strand downstream of exon 9, fortuitously flanked by sequences in good agreement with the splicing consensus cag/G and CAG/gtaagt (22; Figure 4B ).
In contrast to the constitutive exons, the cassette exons 3, 4A and 8 were absent from the mRNA of the expression constructs ( Figure 3, constructs 1, 3 and 6 ). In the case of exon 3, the genomic insert in the expression construct also carried the 3' half of exon 2; the exon 2 fragment did not inhibit splicing nor produce aberrant products. In the case of exon 4A, insertion of the relevant fragment into pSPLl in either orientation gave no spliced product besides the vector (data not shown). In the case of exon 8, the genomic insert used for the expression construct also carried exon 9, which was captured. The behavior of exon 6 depends on the identity of the flunking exons Expression constructs containing cassette exon 6 were made with either homologous or heterologous (insulin) flanking exons. Interestingly enough, exon 6 was excluded from the construct mRNA from COS cells if flanked by exons 5 and 7, but was included if flanked by insulin exons 2 and 3 ( Figure 3 , constructs 4 and 5, respectively). Furthermore, when exon 6 was flanked by heterologous exons (construct 5), it gave rise to three different splicing products, arising from uniform utilization of the correct 5' splice site coupled to alternative 3' splice sites ( Figure 3B and 4A, bands A, B and C). In fact, the major PCR product corresponded not to the authentic splice site of exon 6 ( Figure 3B and 4B, band A) but to a site within the exon ( Figure 3B and 4A, band B) slighdy closer to the 3' splice consensus of cag/G (22) . However, other sites widiin exon 6 equally similar to the consensus were ignored. There is clearly a dichotomy between exons 4A and 6, because in the 4A construct the tau exon was flanked by heterologous exons and was completely excluded (data not shown). On the other hand, constitutive exon 4 was captured even though it was flanked by heterologous exons (Figure 3, construct 2 ).
DISCUSSION
In this study, a cosmid containing both constitutive and alternative (cassette) exons of the human tau gene was used as a model substrate for exon trapping (9) . The results from the expression constructs indicate that all the constitutive tau exons on the cosmid are amplified by this assay regardless of size: the constitutive exons range from 56 (exon 5) to 266 nucleotides (exon 9). Also, it does not seem to matter whether one or more constitutive exons are within a genomic fragment (for example, exons 5 and 7 are trapped as a unit) nor whether the constitutive exons are flanked by heterologous ones (for example, exon 4).
The situation is very different for alternative exons. In the case of tau, all die alternatively spliced exons on x6 are cassettes and under different phenotypic regulation: 2 and 3 are small exons with large introns (1,6) which are developmentally regulated in the central nervous system (4) (5) (6) (7) (8) . Furthermore, exon 3 is never incorporated without exon 2, making it an ambiguous entity between a true cassette and a member of a coordinated exon pair. Conversely, 4A and 6 are large exons with small introns (1, 6) which until now have only been found in the peripheral nervous system or cell lines derived therefrom (2, 3). The phenotypic regulation of exon 8 is unclear; it has been found in bovine brain, but not yet in tau cDNAs of either the human central (1) may be dictated by the extremely poor agreement of its splice sites with the consensus (1, 22) . For exon 6, the identity of the flanking exons appears crucial. The homologous tau exons suppress it, whereas heterologous exons allow its inclusion. The involvement of the flanking exons in splicing selection seen in the case of exon 6 has been documented for the cardiac troponin T cassette miniexon (24) , as well as for the mutually exclusive exons of myosin light chain 1/3 (25) . Regardless of die mechanisms operating on selection of exon 6, what is important for the validity of the exon trapping assay is the fact that, when exon 6 is captured, it gives multiple products.
The behavior of exon 6 and the capture of a random sequence from the nonsense strand near exon 9 indicate that context is as important in me trapping assay as in splicing itself. The splice sites of the alternative tau exons conform less well to the consensus (22) than those of the constitutive ones (1) and almost certainly are involved in regulation. It is also interesting that me sequences which give rise to products B, C and X have neither a long polypyrimidine tract nor a likely branch point (26, 27) .
The sensitivity of the trapping assay (it contains two amplification steps, the intracellular increase in plasmid copy number caused by the T antigen and the PCR reaction) can clearly lead to artifacts. Insertion of certain genomic fragments may give false positives: Pseudoexons such as that within the intron between exons 8 and 9 seem to conform to the size and boundary requirements for real exons ( Figure 4B ). One reading frame of this captured sequence even gives a continuous peptide, though not one corresponding to any known protein within the nonredundant combined peptide database (28) . Thus, one of the advantages ascribed to the assay-namely, the retrieval of exons without need of cDNA isolation (9)-needs to be qualified. Furthermore, use of this assay may lead to both under-and overestimation of possible mRNA species: retrieval of differing products need not indicate alternative splicing per se; exon 6 has always been isolated as an entire unit (2, 3, 6) , so the band B and C products ( Figure 3B ) would lead to the conclusion that it actually has multiple 3' splice sites. On the other hand, isolation of variant products may yield some information about the regulation of alternative exons.
Taken together, the results from uiis study suggest that this particular method of exon identification will generally not unmask all alternatively spliced exons. It will give the skeleton outline of a gene, i.e. the constitutive exons; it will also capture certain subclasses of alternative exons.
